A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice

There is an ongoing need to develop strategic combinations of therapeutic agents to prevent type 1 diabetes (T1D) or to preserve islet β-cell mass in new-onset disease. Although clinical trials using candidate therapeutics are commonly based on preclinical studies, concern is growing regarding the r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes
Päätekijät: Gill, Ronald G., Pagni, Philippe P., Kupfer, Tinalyn, Wasserfall, Clive H., Deng, Songyan, Posgai, Amanda, Manenkova, Yulia, Bel Hani, Amira, Straub, Laura, Bernstein, Philip, Atkinson, Mark A., Herold, Kevan C., von Herrath, Matthias, Staeva, Teodora, Ehlers, Mario R., Nepom, Gerald T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Diabetes Association 2016
Aiheet:
Immunology and Transplantation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5860426/
https://ncbi.nlm.nih.gov/pubmed/26718498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db15-0492
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia